Download Stanford Profiles: /viewCV

Heather Wakelee, M.D.
Assistant Professor
Department of Medicine, Division of Oncology
Stanford University
Stanford Clinical Cancer Center
875 Blake Wilbur Drive
Stanford, CA 94305-5826
(650) 498-6000
Education
1992
1996
A.B. in Molecular Biology, Magna cum laude
Princeton University, Princeton, New Jersey,
M.D., Johns Hopkins University School of Medicine,
Baltimore, Maryland
Postgraduate Training
1996-97
Internship in Internal Medicine
Stanford University School of Medicine, Stanford, California
1997-99
Residency in Internal Medicine
Stanford University School of Medicine, Stanford, California
1999-00
Chief Residency in Internal Medicine
Stanford University School of Medicine, Stanford, California
2000-03
Fellowship in Medical Oncology
Stanford University School of Medicine, Stanford, California
2002
AACR/ASCO Joint Workshop, Methods in Clinical Cancer Research
Vail, Colorado, July 27- August 2, 2002
Academic/Clinical Appointments
2003-04
Staff Physician, Division of Oncology
Stanford University School of Medicine, Stanford, California
2004 -06
Clinical Instructor, Division of Oncology
Stanford University School of Medicine, Stanford, California
2006
Assistant Professor of Medicine, Division of Oncology
Stanford University School of Medicine, Stanford, California
Honors
1992
1996
1999-00
2003
2005
2007
2/1/05
Sigma Xi
Alpha Omega Alpha
Chief Resident, Stanford Department of Internal Medicine
American Society of Clinical Oncology Merit Award Recipient
Women Against Lung Cancer Travel Grant Award
– 11th World Conference on Lung Cancer
Oncology Division Teaching Award
1
2008
2008
Recipient, Stanford Cancer Center Developmental Cancer Research
Award (DCRA)
Oncology Division Teaching Award
Board Certification
1999
American Board of Internal Medicine, Internal Medicine
2003
American Board of Internal Medicine, Medical Oncology
National Committees
2005-07
2004 -07
2002 2006 2006 2007
2008 -
American Society of Clinical Oncology –
Scientific Program Committee – Lung Cancer Track, 2005 - 07
American Society of Clinical Oncology –
Oncology Compendium Project 2004 -2006
Education Committee Lung Cancer Track, 2004 -2007
Eastern Cooperative Oncology Group (ECOG) Thoracic Core Committee
International Association for the Study of Lung Cancer (IASLC) World
Congress 2009 Local Organizing Committee
Co-Chair – Fellows Day
National Lung Cancer Partnership (formerly Women Against Lung
Cancer) – Mentoring Committee
American Society of Clinical Oncology Continuing Medical Education Reviewer at 2007 Annual Meeting
National Lung Cancer Partnership – Scientific Committee
University Committees
2005-2007
2005 2006-2007
2006200620062006
20072008
Cancer Center Research Database Committee–
Core Development Member
Disease Management Committee–
Thoracic Oncology Team Leader
Cancer Center Clinical Trial Design and Biostatistics Committee
Internal Medicine Residency Interviewer
Stanford Faculty Senate
alternate member
Course Director of MED 322A, Medical Oncology Clinics at Stanford
University School of Medicine
Course Director of MED 321A, Medical Oncology Inpatient Rotation
at Stanford University School of Medicine
Stanford Scientific Review Committee member
Search committee member for radiation oncology assistant professor in
thoracic –MCL
2
2008
2008
2008
Search committee member for thoracic surgery assistant professor –
MCL
Search committee member for medical oncology –thoracic- assistant
professor-MCL
Mentor for Stanford University medical students in MED 313 –
ambulatory medicine
Professional Societies
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
International Association for the Study of Lung Cancer (IASLC)
National Lung Cancer Partnership (formerly Women Against Lung Cancer)
Editorial Positions
Current Treatment Options in Oncology (section editor, lung cancer 2005-)
Journal of Medical Case Reports (associate editor, Oncology 2008-)
Peer-Reviewer
American Journal of the Medical Sciences, American Journal of Clinical Oncology, Annals of
Oncology, British Journal of Cancer, Cancer, Clinical Cancer Research, Clinical Lung Cancer,
Core Evidence, Drugs & Aging, Expert Opinion on Pharmacotherapy, Journal of Clinical
Oncology, Journal of Thoracic Oncology, Lancet Oncology, Cancer Chemotherapy and
Pharmacology
Peer-Reviewed Publications
1. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, Nguyen H,
Wine JJ. delta-F508-CFTR channels: kinetics, activation by forskolin, and
potentiation by xanthines. American Journal of Physiology 270 (Cell Physiology 39):
C1544-C1555, 1996.
2. Wakelee H, Ramalingam S, Belani CP. Docetaxel in advanced non-small cell lung
cancer. Expert Review of Anticancer Therapy. Vol 5 (1):13-24, 2005.
3. Wakelee H, Fisher GA. A Phase I Trial of Irinotecan (CPT-11) with Amifostine in
Patients with Metastatic Colorectal Cancer. Investigational New Drugs. Vol 23
(3):241-2, 2005.
4. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks
RS, Perry MC, Livingston RB, Johnson DH, for the Eastern Cooperative Oncology
Group. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT)
following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does
not increase the expected risk of death from intercurrent disease (DID) in Eastern
3
Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer. Vol 48 (3):389-397,
2005.
5. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI.
A Phase II Study of IFOX Therapy (Gefitinib, 5-Fluorouracil, Leucovorin,
Oxaliplatin) in Previously Treated Patients with Metastatic Colorectal Cancer.
Journal of Clinical Oncology. Vol 23 (24):5613-9, 2005.
6. Wakelee HA, Sikic BI. Activity of novel cytotoxic agents in lung cancer:
epothilones and topoisomerase I inhibitors. Clinical Lung Cancer. Vol 7 (Suppl
1):S6-12, 2005.
7. Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial
growth factor receptor small-molecule inhibitors: novel agents with potential in
lung cancer. Clinical Lung Cancer. Vol 7 (Suppl 1):S31-8, 2005.
8. Le Q-T, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W,
Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O’bryne KJ, Koong AC,
Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients
with early stage non-small cell lung cancers. Clinical Cancer Research. Vol 12
(5):1507-12, 2006.
9. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the Natural
History of Non-Small Cell Lung Cancer (NSCLC): Comparison of Outcome and
Patient Characteristics in Advanced NSCLC Patients Entered in Eastern
Cooperative Oncology Group (ECOG) Trials from 1981-1990 versus 1991-2000.
Cancer. Vol 106(10):2208-17, 2006.
10. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson
DH. Survival differences by sex for patients with advanced non-small cell lung
cancer on Eastern Cooperative Oncology Group trial 1594. Journal of Thoracic
Oncology Vol 1 (5):441-446, 2006.
11. Cabebe E, Wakelee H. Sunitinib – A newly approved small molecule inhibitor of
angiogenesis. Drugs of Today (Barcelona). Vol 42(6):387-398, 2006.
12. Donington JS, Le QT, Wakelee HA. Lung cancer in women: Exploring sex
differences in susceptibility, biology and therapeutic response. Clinical Lung
Cancer Vol 8(1):22-9, 2006.
13. Roy MS, Le Q-T, Donington JS, Wakelee HA. A multi-disciplinary approach to
management in a patient with bilateral superior sulcus non-small cell lung
carcinoma. Clinical Lung Cancer Vol 8(2):146-8, 2006.
4
14. Le Q-T, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu
D, Whyte RI, Donington J. Results of a phase I dose escalation study using single
fraction stereotactic radiotherapy for lung tumors. Journal of Thoracic Oncology Vol
1(8):802-9, 2006.
15. Wakelee HA, Chang ET, Gomez SL, Keegan THM, Feskanich D, Clarke CA,
Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. Lung cancer incidence
in never-smokers. Journal of Clinical Oncology Vol 25(5):472-478, 2007.
16. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell
lung cancer -How to handle stage I disease. The Oncologist Vol 3(12):331-7, 2007.
17. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, Le Q-T,
Wakelee HA, Donington JS, Graves EE, Loo BW. Metabolic tumor burden
predicts for disease progression and death in lung cancer. International Journal of
Radiation Oncology, Biology, Physics Vol 69(2):328-33, 2007.
18. Ganjoo KN, Wakelee H. Review of Erlotinib in the treatment of advanced nonsmall cell lung cancer. Biologics: Targets & Therapy Vol 1(4):335-46, 2007.
19. Witteles WH, Schrier SL, Wakelee HA. Lung cancer presenting with
amegakaryocytic thrombocytopenia. Journal of Clinical Oncology Vol 26(7):1171-4,
2008.
20. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F,
Choy H, Gandara DR. Cooperative group research efforts in lung cancer: Focus
on early stage non-small cell lung cancer. Clinical Lung Cancer Vol 9(1):9-15, 2008.
21. Wakelee H. Antibodies to the vascular endothelial growth factor (VEGF) in nonsmall cell lung cancer (NCSLC). Journal of Thoracic Oncology Vol 3(6 Suppl 2):S1138, 2008.
22. Langer C, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes E, Adjei A, Baas P,
Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small
cell lung cancer (NSCLC): Are we making progress?. Clinical Lung Cance. Vol
9(2):85-91, 2008.
23. Padda S, Kothary N, Donington J, Cannon W, Loo BW, Kee S, Wakelee H.
Complications of Ablative Therapies in Lung Cancer. Clinical Lung Cancer. Vol
9(2):122-6, 2008.
5
24. Hsu JY, Wakelee H. Pemetrexed disodium for the treatment of non-small cell
lung cancer (NSCLC). Drugs of Today Vol 44(9):669-678, 2008.
25. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Goss G,
Gaspar L, Gandara DR, Choy H, Putnam JB. Cooperative group research efforts in
lung cancer 2008: focus on advanced-stage non-small cell lung cancer. Clinical Lung
Cancer Vol 9(6):346-51, 2008.
26. West HL, Wakelee HA, Perry MC, Belt RJ, Chen R, Obasaju C. Gemcitabine and
pemetrexed administered in rapid sequence as front-line chemotherapy for
advanced non-small-cell lung cancer: A phase II clinical trial. Annals of Oncology
Epublished Jan 15, 2009.
27. Krupitskaya Y, Eslamy H, Nguyen DD, Kumar A, Wakelee HA. Osteoblastic bone
flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving
bevacizumab in addition to standard chemotherapy. Journal of Thoracic Oncology
Vol 4(3):429-31, 2009.
28. Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung
cancer. Proceedings of the American Thoracic Society (in press).
Other Publications
1.
Wakelee H, Kelly K. Novel approaches for the treatment of small cell lung
cancer. Hematology/Oncology Clinics of North America. Vol 18 (2):499-518, 2004.
2.
Alberts, WM, Vaporciyan AA, Wakelee H. Turning the tide: New directions
for the treatment of early stage non-small cell lung cancer. American Thoracic
Society Newsletter. July:1-12, 2005.
3.
Wakelee H, Polsdorfer R. Adjuvant Chemotherapy in NSCLC. Bay Area
Oncology News. Vol 1 (3):6-9, 2005.
4.
Kumar A, Wakelee H. Second-and third-line treatments in non-small cell lung
cancer. Current Treatment Options in Oncology. Vol 7 (1):37-49, 2006.
5.
Wakelee H, Belani CP. Optimizing first-line treatment options for patients
with advanced NSCLC. The Oncologist. Vol 10 (suppl 3):1-10, 2005.
6.
Wakelee H, Gandara DR. North American cooperative group research efforts
in lung cancer. Syrigos KN, Nutting CM, Roussos C (eds) Tumors of the Chest:
Biology, Diagnosis and Management. Germany: Springer-Verlag, 2006;451-461.
7.
Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant
chemotherapy for stage IB non-small-cell lung cancer: implications for the new
intergroup trial. Clinical Lung Cancer Vol 8(1):18-21, 2006.
6
8.
Cabebe E, Wakelee H. Adjuvant and neoadjuvant treatment in early stage
non-small-cell lung cancer. Sandler AB (eds) New Treatment Paradigms in NonSmall-Cell Lung Cancer. Manhasset, New York: CMPMedica, 2006:1-25.
9.
Wakelee HA, Brahmer J, Siegfried JM. Should sex play a role in treatment
decisions for non-small cell lung cancer?. Govindan R (eds) American Society of
Clinical Oncology Education Book 2007. Alexandria, Virginia: American Society
of Clinical Oncology, 2007:395-399.
10.
Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC.
Current Treatment Options in Oncology. Vol 8 (1):15-27, 2007.
11.
Gandara DR, Wakelee H, Calhoun R, Jablons D. Adjuvant Chemotherapy of
stage I non-small cell lung cancer in North America. Journal of Thoracic
Oncology. Vol 2 (7 Suppl 3):S125-7, 2007.
12.
Wakelee HA. Sex differences in the natural history and treatment of NSCLC
[expert column]. Medscape Hematology-Oncology September 28, 2007. Available
at: http://www.medscape.com/viewarticle/562967
13.
Wakelee H. Newly diagnosed, advanced-stage non-small-cell lung cancer:
Considerations for first-line treatment. Advances in Lung Cancer. Vol 7(4):3-7,
2007.
14.
Wakelee HA, Gomez SL, Chang ET. Sex differences in lung-cancer
susceptibility: a smoke screen? Lancet Oncology. Vol 9(7):609-10, 2008.
15.
Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, Espinoza-Delgado I, Govindan
R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC,
Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M,
Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in
the treatment of lung cancer: Fifth Cambridge Conference assessing
opportunities for combination therapy. Journal of Thoracic Oncology. Vol 3(6
Suppl 2):S107-12, 2008.
16.
Wakelee H. Lung cancer in non-smokers. Rose BD (eds). UpToDate. Waltham,
MA: UpToDate, 2008
17.
Wakelee H. Adjuvant therapy in non-small cell lung cancer [expert column].
Medscape Hematology-Oncology. July 17, 2008. Available at:
http://www.medscape.com/viewarticle/577353
18.
Kumar A, Wakelee H. Second-line chemotherapy: More choices than ever
before. Govindan R (eds). New Treatment Strategies in Metastatic Lung Cancermonograph. Manhasset, NY: CMPMedica, 2008:51-72.
19.
Cabebe E, Wakelee H. Current status of adjuvant therapy in non-small cell
lung cancer. Govindan R, Langer CJ (eds). E-Updates in Lung Cancer:
Controversies and Challenges Volume II: A COAB Online Update Series. The
7
Oncology Group, CMP Medica, Inc. posted July 29, 2008. Available at:
http://www.cancernetwork.com/display-cme/article/10165/1168318.
20.
Wakelee H, Chhatwani L. Adjuvant chemotherapy for resected non-small cell
lung cancer. Seminars in Thoracic and Cardiovascular Surgery Vol 20(3):198-203,
2008.
21.
Wakelee H. Lung cancer in never-smokers. Tina M. St. John (eds). With Every
Breath: A Lung Cancer Guidebook. Vancouver, WA: Tina M. St. John, (in press)
Abstracts (20 of 42)
1. Jacobs C, Wakelee H, Loewen G, Berg K, Rowinsky E, Hammond L, Chu Q,
Schindler K, Flanagan S, Takimoto C. Phase I pharmacokinetic (PK) study of
bexarotene in combination with paclitaxel and carboplatin in patients with
advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of
Clinical Oncology 22:696, 2003 (abstract 2798).
2. Le Q-T, Ho A, Cotrutz C, Wakelee H, Kee ST, Donington J, Whyte RI. Single
fraction stereotactic radiosurgery (SFSR) for lung tumors – A phase I dose
escalation trial. Proceedings of the American Society of Clinical Oncology 23:670, 2004
(abstract 7231). Poster presentation.
3. Fisher G, Advani R, Wakelee H, Jacobs C, Gladysheva K, Fitzgerald A, Sikic B. A
Phase I trial of Oblimersen and Gemcitabine in refractory and advanced
malignancies. Journal of Clinical Oncology – 2005 American Society of Clinical
Oncology Annual Meeting Proceedings 23(16S):234s, 2005 (abstract 3174).
4. Advani R, Gordon M, Hurwitz H, Mendelson D, Wakelee H, Ebbinghaus S, Hoch
U, Silverman J, Havrilla N, Adelman D. Phase I trial of SNS-595 in patients with
advanced malignancies. Journal of Clinical Oncology – 2005 American Society of
Clinical Oncology Annual Meeting Proceedings 23(16S):159s, 2005 (abstract 2099).
5. Wakelee H, Jacobs C, Loewen G, Berg K, Rowinsky E, Hammond L, Chu Q,
Schindler K, Flanagan S, Takimoto C. Effect of bexarotene on paclitaxel and
carboplatin pharmacokinetics (PK) during a phase I study in patients with
advanced non-small cell lung cancer (NSCLC). Presented as part of the 4th
International Lung Cancer Congress. Maui, Hawaii June 25-28, 2003. Poster.
6. Wakelee H, Middleton G, Dunlop D, Kelly C, Ramlau R, Leighl N, Hao D,
Zatloukal P, Loewen G, Cox K, Jacobs C. Effect of bexarotene on vinorelbine and
cisplatin pharmacokinetics (PK) during a Phase I study in patients with advanced
non-small cell lung cancer (NSCLC). Lung Cancer 49 (suppl 2):S274, 2005 (abstract
P-592). Poster presentation.
8
7. Advani A, Gordon M, Hurwitz H, Mendelson D, Wakelee H, Ebbinghaus S, Hoch
U, Silverman J, Havrilla N, Adelman D. Phase I trial of SNS-595 in patients (pts)
with advance malignancies. Proceedings of the AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics:151, 2005 (abstract B100).
Poster presentation.
8. Patnaik A, Wakelee H, Mita M, Fitzgerald AM, Hill M, Fox NL, Howard T, Ullrich
S, Tolcher A, Sikic B. HGS-ETR2: A fully human monoclonal antibody to TRAILR2: Results of a phase I trial in patients with advanced solid tumors. Journal of
Clinical Oncology – 2006 American Society of Clinical Oncology Annual Meeting
Proceedings 24(18S):123s, 2006 (abstract 3012). Oral presentation (Clinical Science
Symposium).
9. Wakelee HA, Adjei AA, Halsey J, Lensing JL, Dugay JD, Hanson LJ, Reid JM,
Piens JR, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a
novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid
malignancies (ASM). Journal of Clinical Oncology – 2006 American Society of
Clinical Oncology Annual Meeting Proceedings 24(18S):131s, 2006 (abstract 3044).
Poster discussion presentation.
10. Hurwitz H, Gordon M, Advani R, Ebbinghaus S , Mendelson D, Wakelee H, Hoch
U, Silverman J, Havrilla N, Adelman D. SNS-595 demonstrates clinical activity and
dose-proportional pharmacokinetics (PK) in two phase I clinical trials. Journal of
Clinical Oncology – 2006 American Society of Clinical Oncology Annual Meeting
Proceedings 24(18S):136s, 2006 (abstract 3062). Poster presentation.
11. Wakelee HA, Dahlberg SE, Schiller JH, Langer CJ, Sandler AB, Brahmer JR, Belani
CP, Johnson DH. Menopausal status of women may affect survival in advanced
NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies
using age of 60 years or older as a surrogate marker. Journal of Thoracic Oncology 12th World Conference on Lung Cancer Proceedings 2(8(Suppl 4)):S570, 2007
(Abstr #P1-052). Poster presentation.
12. Kraut MJ, Kumar A, San Pedro-Salcedo M, Terebelo H, Wakelee H. Safety of
gemcitabine and carboplatin plus bevacizumab for advanced stage non-small cell
lung cancer (NSCLC): pooled preliminary safety data from two ongoing studies.
Journal of Thoracic Oncology -12th World Conference on Lung Cancer Proceedings
2(8(Suppl 4)):S724, 2007 (Abstr #P3-107). Poster presentation.
13. Loo BW, Lee P, Weerasuriya DK, Lavori PW, Quon A, Maxim PG, Le Q-T,
Wakelee HA, Donington JS, Graves EE. Metabolic tumor volume predicts disease
9
progression and overall survival in lung cancer. Journal of Thoracic Oncology -12th
World Conference on Lung Cancer Proceedings 2(8(Suppl 4)):S582, 2007 (Abstr
#P1-082). Poster presentation.
14. Sikic BI, Wakelee HA, von Mehren M, Lewis N, Calvert AH, Plummer ER, Fox
NL, Howard T, Jones SF, Burris HA. A phase Ib study to assess the safety of
lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in
combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. Proceedings
of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics:124, 2007 (abstr). Poster presentation.
15. Wakelee HA, Fehling JM, Molina JR, Lensing JL, Funke RP, Miles D, Sikic BI. A
phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally
daily to patients (pts) with advanced solid malignancies (ASM). Journal of Clinical
Oncology – 2008 American Society of Clinical Oncology (ASCO) Annual Meeting
Proceedings 26(15S):160s, 2008 (abstr 3528). Poster discussion presentation.
16. Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Costa D, Vrindavanam
N, Yanagihara R, Pennell N, Lynch TJ. Activity and tolerance of XL647 in NSCLC
patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II
trial. Journal of Clinical Oncology – 2008 American Society of Clinical Oncology
(ASCO) Annual Meeting Proceedings 26(15S):430s, 2008 (abstr 8028). Poster
discussion presentation.
17. Loo B, Chapman C, Rao A, Shen J, Quinlan-Davidson S, Filion E, Johnson G, Zhou
L, Dieterich S, Maxim P, Wakelee H, Whyte R, Le Q-T.Tumor Size is a Critical
Determinant of Local Control in Single Fraction Stereotactic Radiotherapy of
Pulmonary Tumors. Proceedings of the 50th Annual Meeting of the American
Society of Therapeutic Radiology and Oncology (ASTRO), 2008. (abstr 2667).
Poster presentation.
18. Wakelee HA, Padda SK, Chhatwani L, San Pedro-Salcedo M, Krupitskaya Y,
Musib L, Latz JE. A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in
combination with erlotinib (ERL) administered orally daily to patients with
advanced solid malignancies. European Journal of Cancer – EJC Supplements 20th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6(12):126s, 2008 (abstr 401). Poster presentation.
19. Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, Sandler
AB, Belani CP, Johnson DH. Increased benefit from bevacizumab (BEV) in
younger women with advanced NSCLC on Eastern Cooperative Oncology Group
(ECOG) E4599. Journal of Thoracic Oncology –Chicago Multidisciplinary Symposium
in Thoracic Oncology 3(11(Suppl 4)):S282, 2008 (Abstr #131). Poster presentation.
10
20. Krupitskaya Y, Padda SK, Chhatwani L, San Pedro-Salcedo M, Musib L, Latz JE,
Wakelee HA. A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in
combination with erlotinib (ERL) administered orally daily to patients with
advanced solid malignancies. IASLC 9th Annual Targeted Therapies for the Lung
Cancer Conference in Santa Monica, CA, February 20, 2009- Oral presentation
Invited Presentations (10 of 110)
1.
Session Chair of the Thoracic Tumor Board at the 9th Annual Multidisciplinary
Management of Cancers: A Case-based Approach (formerly Northern California
Tumor Board at Silverado) presented by Stanford University School of Medicine.
Napa, California, March 16, 2007.
2.
Session Chair of “Should gender by used to choose therapy in non-small cell lung
cancer” and speaker on “Differential Response/Survival by Sex in NSCLC with
Conventional Therapy” as part of the American Society of Clinical Oncology
annual meeting in Chicago, Illinois on June 2, 2007.
3.
“Chemotherapy and Radiation Strategies Pre-and Post-Operatively for Non-Small
Cell Lung Cancer (NSCLC).” Presented at Updates in Thoracic Surgery conference
coinciding with the 60th anniversary of the Beijing Shunyi District Hospital,
Shunyi, China on October 28, 2007.
4.
“Adjuvant Chemotherapy for Lung Cancer.” Presented at the American
Association of Thoracic Surgery (AATS) General Thoracic Surgery Symposium in
San Diego, CA, May 11, 2008.
5.
Session Chair of “Adjuvant Chemotherapy for NSCLC: Who, What, When” and
speaker on “What: Overview of Current Data”, an education session as part of the
American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL on
May 31, 2008 and repeated on June 2, 2008.
6.
“Resectable Lung Cancer: Adjuvant/Neo-Adjuvant Therapy.” Presented at the
Fifth Annual Fall Oncology Conference in Birmingham, AL on October 25, 2008.
7.
“Adjuvant Therapy: State of the Art in 2008.” Presented at the 10th annual
UCSF/UC Davis Thoracic Oncology Conference in San Francisco, CA on
November 8, 2008.
8.
“Angiogenesis Inhibitors in Lung Cancer: Where Do We Go From Here.”
Presented at the Fifth Annual Symposium on the Future of Lung Cancer in Reston,
VA on December 6, 2008.
11
9.
“Present and Future of Adjuvant Therapy in Early Stage NSCLC” As part of the
6th Annual Atlanta Lung Cancer Symposium in Atlanta, Georgia on February 7,
2009.
10. “XL647” presented at the 9th Annual Targeted Therapies for the Lung Cancer
Conference in Santa Monica, CA, February 20, 2009.
12